Since the early 2000s, CRC mortality has significantly decreased, largely due to advancements in screening and the removal of precancerous polyps. However, CRC continues to be the second most common ...

LEIDEN, Netherlands--(BUSINESS WIRE)--Ncardia, a leading human iPSC company, announced today the launch of a new panel of ready-to-use assays designed to streamline the screening and selection of new ...

As researchers race to identify new therapeutics, streamlined antibody discovery processes have never been more crucial, and the need for speed and efficiency is paramount. The development of ...

Patients with an average risk for colorectal cancer (CRC) are candidates for noninvasive tests, such as multitarget stool DNA (mtsDNA), whereas those with a higher risk, including those with a family ...